INKT - MiNK Therapeutics, Inc.

10.95
0.220   2.009%

Share volume: 34,802
Last Updated: 04-24-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$10.73
0.22
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 43%
Liquidity 31%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-14.59%
1 Month
20.00%
3 Months
-14.32%
6 Months
-24.69%
1 Year
42.21%
2 Year
1,156.89%
Key data
Stock price
$10.95
P/E Ratio 
0.00
DAY RANGE
$10.43 - $11.51
EPS 
-$2.10
52 WEEK RANGE
$6.34 - $76.00
52 WEEK CHANGE
$46.00
MARKET CAP 
63.321 M
YIELD 
N/A
SHARES OUTSTANDING 
4.694 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
01-28-2025
NEXT EARNINGS DATE
05-13-2025
BETA 
1.37
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$72,897
AVERAGE 30 VOLUME 
$71,570
Company detail
CEO: Jennifer S. Buell
Region: US
Website: minktherapeutics.com
Employees: 30
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

MiNK Therapeutics, Inc. engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate, AGENT-797, is in Phase 1 clinical trials.

Recent news